2022
DOI: 10.1016/j.ajpc.2022.100372
|View full text |Cite
|
Sign up to set email alerts
|

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
6
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(6 citation statements)
references
References 60 publications
0
6
0
Order By: Relevance
“…Interestingly, a recent post hoc analysis of the BETonMACE study indicates that apabetalone was associated with a lower incidence of ischemic MACE and hospitalization for heart failure in patients with type-2 diabetes, coronary artery disease, and a moderate-to-high likelihood of advanced nonalcoholic liver fibrosis. 45 On the other hand, apabetalone had little to no benefit among individuals with a modest likelihood of liver fibrosis. 45 Nevertheless, patients receiving apabetalone show a significant reduction in the progression of liver fibrosis as compared to placebo over a period of 26.5 months.…”
Section: Cardiovascular Diseasementioning
confidence: 99%
See 2 more Smart Citations
“…Interestingly, a recent post hoc analysis of the BETonMACE study indicates that apabetalone was associated with a lower incidence of ischemic MACE and hospitalization for heart failure in patients with type-2 diabetes, coronary artery disease, and a moderate-to-high likelihood of advanced nonalcoholic liver fibrosis. 45 On the other hand, apabetalone had little to no benefit among individuals with a modest likelihood of liver fibrosis. 45 Nevertheless, patients receiving apabetalone show a significant reduction in the progression of liver fibrosis as compared to placebo over a period of 26.5 months.…”
Section: Cardiovascular Diseasementioning
confidence: 99%
“…Nevertheless, patients receiving apabetalone show a significant reduction in the progression of liver fibrosis as compared to placebo over a period of 26.5 months . An important limitation of this study is that there was no liver histology or imaging to support the hepatic fibrosis score data . Thus, further research is needed to assess the hepatic and cardiovascular effects of apabetalone in patients with nonalcoholic liver fibrosis.…”
Section: Apabetalone In the Treatment Of Cardiovascular Diseasementioning
confidence: 99%
See 1 more Smart Citation
“…Table 2 summarizes the trial results showing a significant reduction in primary HRs and Cis outcomes for indicating composite and component endpoints [ 103 ]. Although, in a post-hoc analysis of the BETonMACE trial, including patients with T2D, recent acute coronary disease, and a moderate likelihood of NAFLD, apabetalone reduced the risk of MACE [ 104 ].…”
Section: Is There a Possible Therapeutic Related To Epigenetics?mentioning
confidence: 99%
“…Although this conceptual framework is generally related to cardiometabolic disease, it might be easily translated to other chronic and time-dependent conditions such as neurodegenerative pathologies, autoimmune diseases, and cancer. As indirect evidence, epigenetic pan-deactivators of vascular inflammation as the inhibitors of bromodomain and extraterminal domain (BET) proteins [96] have recently been proposed for all these disease settings [97][98][99][100][101][102][103]. Similarly, anti-inflammatory drugs are attracting substantial attention in the context of CV diseases [104].…”
Section: The Link Between Inflammation and Early Microvascular Ageingmentioning
confidence: 99%